Bristol-Myers Squibb Aktie News

Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (“BMS”) (NYSE: BMY), signing a new Commercial Supply Agreement (CSA) for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.

All three have encountered headwinds in recent years. But they have also made progress toward addressing them.

Bristol Myers Squibb (BMY) has delivered a ~27% total return in three months, driven by topline growth and dividend strength. With the valuation rebound largely complete, BMY shifts from a high-conviction rerating to a balanced Hold, recommending disciplined profit-taking. Execution and regulatory risks remain around replacing Eliquis revenues, with CELMoDs and CAR-T progress critical to the lo...

Bristol Myers Squibb just announced an important partnership with Microsoft that involves AI. Intuitive Surgical has integrated AI real-time processing into its surgical robots, but that could be just the start.

Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market, leveraging TRACTr technology for long-term oncology growth. Camzyos delivered 89% YoY revenue growth and promising phase 3 SCOUT-HCM results, supporting potential label exp...

Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb ​to develop a new cancer treatment, ‌sending its shares up more than 12% in premarket trading.